Treatment Pause Versus Treatment Continuation in IMDC Good or Intermediate Risk With Only One Adverse Prognostic Factor in mRCC Patients With an Objective Response at 12 Months of Treatment With PD1/ PDL1 ICIs + VEGFR-Tyrosine Kinase Inhibitors

NCT05219318 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

22

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Renal Cell Carcinoma
Good or Only One Adverse Prognostic Factor Intermediate Risk Per IMDC Score

Interventions

DRUG: Combination PD-1/PD-L1 ICI + VEGFR-TKI
OTHER: Treatment pause

Sponsor

University Hospital, Bordeaux